Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-15
2005-11-15
Krass, Frederick F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S908000
Reexamination Certificate
active
06964959
ABSTRACT:
The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing methylol-containing compound. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
REFERENCES:
patent: 3423408 (1969-01-01), Pfirrmann
patent: 3963706 (1976-06-01), Pfirrmann
patent: 4096241 (1978-06-01), Geistlich et al.
patent: 4107305 (1978-08-01), Pfirrmann
patent: 4226858 (1980-10-01), Pfirrmann et al.
patent: 4337251 (1982-06-01), Pfirrmann
patent: 4587268 (1986-05-01), Pfirrmann
patent: 4604391 (1986-08-01), Pfirrmann
patent: 4626536 (1986-12-01), Pfirrmann
patent: 4772468 (1988-09-01), Pfirrmann
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5573771 (1996-11-01), Geistlich et al.
patent: 5593665 (1997-01-01), Pfirmann et al.
patent: 5744499 (1998-04-01), Quash et al.
patent: 5819748 (1998-10-01), Pfirmann
patent: 5954687 (1999-09-01), Baudino
patent: 5972933 (1999-10-01), Pfirmann
patent: 5976822 (1999-11-01), Landrum et al.
patent: 6011030 (2000-01-01), Pfirmann
patent: 6080397 (2000-06-01), Pfirmann et al.
patent: 6117868 (2000-09-01), Pfirmann
patent: 6303596 (2001-10-01), Morrissey et al.
patent: 6429224 (2002-08-01), Calabresi et al.
patent: 6703413 (2004-03-01), Calabresi et al.
patent: 0253662 (1988-01-01), None
patent: 1066830 (2001-01-01), None
patent: WO 90/06138 (1990-05-01), None
patent: WO 91/13628 (1991-09-01), None
patent: WO 92/00743 (1992-01-01), None
patent: WO 94/03174 (1994-02-01), None
patent: WO 98/52572 (1998-11-01), None
patent: WO 99/06114 (1999-02-01), None
patent: WO 99/34805 (1999-07-01), None
Blenkharn et al. (1987) “The Antibacterial and Anti-Endotoxin Activity of Taurolidine in Combination with Antibiotics,” Surg. Res. Commun., 2:149-155.
Browne M.K. et al. (1985) “Studies on the Antiendotoxin Properties of Taurolin in Animals and Man,”Recent Advances in Chemotherapy, Proceedings of the 14thInternational Congress of Chemotherapy, Kyoto, pp. 2075-2076.
Browne M.K. et al. (1976) “Taurolin, a New Chemotherapeutic Agent,”The Journal of Applied Bacteriology, vol. 41, pp. 363-368.
Geistlich Catalog, “Taurolin, Triad antimicrobial chemotherapy” pp. I-95. (1989).
Gormans et al. (1987) “Reduced Adherence of Micro -Organisms to Human Mucosal Epithelial Cells Following Treatment with Taurolin, a Novel Antimicrobial Agent,” J. App. Bacteriol., 62:315-320.
Hamik, A. et al. (1997) “Taurolidine Inhibits Tissue Factor Expression in Monocytes,”Abstract from the XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Jun. 6-12.
Jacobi, C. et al. (1999) “New Therapeutic Strategies to Avoid Intra- and Extraperitoneal Metatases during Laparoscopy: Results of a Tumor Model in the Rat,”Digestive Surgery, vol. 16 (5), pp. 393-399.
Jacobi, C. et al. (1997) “Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model,”The American Journal of Surgery, vol. 174 (3), pp. 359-363.
Knight et al., (1983) “NMR Studies and GC Analysis of the Antibacterial Agent Taurolidine,” J. Pharm. Sci. 72:705-707.
Leaper et al. (1985) “Prevention of peritoneal adhesions after thermal injury using noxythidin and Taurolin” in a New Concept in Antimicrobial Chemotherapy for Surgical Infection, eds., WI Bruckner and RW Pfirrman (Urban & Schwarzber: Munich, Vienna, Balt.), pp. 115-119.
McCourt, M. et al. (2000) “Taurolidine Inhibits Tumor Cell Growth In Vitro and In Vivo,”Annals of Surgical Oncology, vol.. 7(9), pp. :685-691.
Monson, J.R.T. et al. (1990) “Preliminary evidence that taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial,”The British Journal of Surgery, vol. 77(6), pp. 711.
Monson, J.R.T. et al. (1990) “Taurolidine as an anti-neoplastic agent: a previously undiscovered role?”The British Journal of Surgery, vol. 77(12).
Monson, J.R.T. et al., (1993) “Taurolidine inhibits tumor necrosis factor (TNF) toxicity new evidence of TNF and endotoxin synergy,”European Journal of Surgical Oncology, 19:226-231.
Raymond, M.A. et al. (2000) “Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator,”Surgical Endoscopy, vol. 14(1), pp. 51-55.
Umpleby, H. et al. (1984) “The efficacy of agents employed to prevent anastomotic recurrence in colorectal carcinoma,”Annals of the Royal College of Surgeons of England, 66:192-194.
Volz, J. et al. (2000) “Modulation of Tumor-Induced Lethality after Pneumoperitoneum in a Mouse Model,”Cancer, vol. 89(2), pp. 262-266.
Wicki, O. et al, (1983) “Solution for Surgical Lavage,”Langenbecks Archiv Für Chirurgie, p. 778, Abstract 276.
Jacobi, C., et al. (1999) “Influence of Different Gases and Intraperitoneal Installation of Antiunllicucul on Cytotoxic Agents on Perltoneal Tumor Cell Growth and Implantation with Lapaoscopic Surgery in a Rat Model,”Burg Endosc, 13: 1021-1025.
International Search Report. PCT/US 00/33104, Issured on Dec. 6, 2001.
Calabresi Paul
Costin James
Darnowski James
Beattie Ingrid A.
Carter Wallace, Inc.
Krass Frederick F.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Rhode Island Hospital
LandOfFree
Use of a methylol-containing compound to treat tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a methylol-containing compound to treat tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a methylol-containing compound to treat tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3515459